Johnson & Johnson International (Singapore) Pte. Ltd. today announced a collaboration with the Singapore Economic Development Board (EDB) to unlock innovation potential in Singapore's life sciences ecosystem. This collaboration is the first of its kind and will leverage Johnson & Johnson Innovation – JLABS' services and innovation resources aimed at boosting the region's innovation output.
Under this collaboration, JLABS will support early-stage companies with a base in Singapore to help accelerate their early-stage discoveries into innovative medicines, medical technologies, and healthcare solutions. JLABS will also collaborate with local incubators and other strategic partners in the ecosystem on venture and talent development offerings to stimulate employment and commercialization opportunities for early-stage companies.
This collaboration with EDB demonstrates the ongoing commitment of Johnson & Johnson to enable and accelerate the best science and technology in the Asia Pacific region with the ambition of addressing critical unmet medical and healthcare needs. It builds on the success of JLABS' no-strings-approach and more than a decade of experience, as well as JLABS' reputation as the largest global network of life science startups, investors, and corporate partners.
"At Johnson & Johnson Innovation, we source and cultivate the world's most promising, early-stage healthcare innovation wherever it originates," said William N. Hait, M.D., Ph.D., Executive Vice President, Chief External Innovation and Medical Officer, Johnson & Johnson. "We are thrilled to partner with EDB to advance the thriving life sciences community in Singapore and help unleash the potential of healthcare innovation in the Asia Pacific region for the rest of the world."
"The needs of the next generation of global innovators, potential partners, and early-stage companies are changing rapidly, and Johnson & Johnson is committed to pioneering new approaches to address them, like this significant collaboration with EDB," said Melinda Richter, Global Head of Johnson & Johnson Innovation – JLABS. "This type of collaboration exemplifies our pivotal role as an innovation, talent, economic and venture developer with a mission to empower our partners with the knowledge, experience, networks and practical frameworks they need to make an impact for patients."
Johnson & Johnson Innovation – JLABS and EDB will be co-hosting a symposium in Singapore before the end of the year, with subsequent announcements emerging from this new collaboration. For companies and innovators interested in JLABS
About Johnson & Johnson Innovation – JLABS
Johnson & Johnson Innovation – JLABS (JLABS) is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology sectors. Our goal is to catalyze and accelerate the delivery of lifesaving, life-enhancing solutions to patients around the world. JLABS is a no-strings-attached model, which means innovators are free to develop their science and technology while holding on to their intellectual property. JLABS also produces campaigns to seek out the best science and technology called QuickFire Challenges.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!